These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39250342)

  • 1. Roflumilast cream (Zoryve) for atopic dermatitis.
    Med Lett Drugs Ther; 2024 Sep; 66(1711):150-151. PubMed ID: 39250342
    [No Abstract]   [Full Text] [Related]  

  • 2. Roflumilast (Daliresp) for COPD.
    Med Lett Drugs Ther; 2011 Jul; 53(1369):59-60. PubMed ID: 21778965
    [No Abstract]   [Full Text] [Related]  

  • 3. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis.
    Smith B; Collier MR; Wu JJ
    JAMA; 2023 Feb; 329(7):594-595. PubMed ID: 36809326
    [No Abstract]   [Full Text] [Related]  

  • 4. Roflumilast Cream vs Vehicle Cream and Chronic Plaque Psoriasis-Reply.
    Lebwohl MG; Hebert AA; Gooderham MJ
    JAMA; 2023 Feb; 329(7):595. PubMed ID: 36809324
    [No Abstract]   [Full Text] [Related]  

  • 5. Polymorphous Light Eruptions Treated With Roflumilast 0.3% Cream: A Case Report.
    Garg KS; Kircik L; Tjahjono L
    J Drugs Dermatol; 2024 Aug; 23(8):686-687. PubMed ID: 39093641
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
    Lebwohl MG; Kircik LH; Moore AY; Stein Gold L; Draelos ZD; Gooderham MJ; Papp KA; Bagel J; Bhatia N; Del Rosso JQ; Ferris LK; Green LJ; Hebert AA; Jones T; Kempers SE; Pariser DM; Yamauchi PS; Zirwas M; Albrecht L; Devani AR; Lomaga M; Feng A; Snyder S; Burnett P; Higham RC; Berk DR
    JAMA; 2022 Sep; 328(11):1073-1084. PubMed ID: 36125472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
    Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H
    J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roflumilast foam (Zoryve) for seborrheic dermatitis.
    Med Lett Drugs Ther; 2024 Apr; 66(1700):57-59. PubMed ID: 38576147
    [No Abstract]   [Full Text] [Related]  

  • 9. Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
    Lebwohl MG; Papp KA; Stein Gold L; Gooderham MJ; Kircik LH; Draelos ZD; Kempers SE; Zirwas M; Smith K; Osborne DW; Trotman ML; Navale L; Merritt C; Berk DR; Welgus H;
    N Engl J Med; 2020 Jul; 383(3):229-239. PubMed ID: 32668113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roflumilast for severe COPD?
    Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild-to-moderate plaque psoriasis.
    Ghani H; Podwojniak A; Tan IJ; Parikh AK; Sanabria B; Rao B
    Skin Res Technol; 2024 Sep; 30(9):e70041. PubMed ID: 39206797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical roflumilast (Zoryve) for plaque psoriasis.
    Med Lett Drugs Ther; 2023 Jan; 65(1668):10-12. PubMed ID: 36651791
    [No Abstract]   [Full Text] [Related]  

  • 13. Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis.
    Uppal SK; Chat VS; Kearns DG; Wu JJ
    J Drugs Dermatol; 2020 Oct; 19(10):956-959. PubMed ID: 33026767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    de Moraes-Souza R; Chahine Chater R; Pera Calvi I; Mesquita Y; Sarto R; Lapenda I; Figueiredo Pereira L; Moury L; Herranz-Pinto P
    Clin Drug Investig; 2024 Sep; 44(9):655-665. PubMed ID: 39172296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and effectiveness of roflumilast cream 0.3% in adults with chronic plaque psoriasis: A 52-week, phase 2, open-label trial.
    Stein Gold L; Adam DN; Albrecht L; Alonso-Llamazares J; Ferris LK; Gooderham MJ; Hong HC; Kempers SE; Kircik LH; Lebwohl M; Loo WJ; Nahm WK; Papp KA; Stewart D; Toth DP; Zirwas M; Krupa D; Snyder S; Burnett P; Higham R; Berk DR
    J Am Acad Dermatol; 2024 Aug; 91(2):273-280. PubMed ID: 38556093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib (Opzelura) for atopic dermatitis.
    Med Lett Drugs Ther; 2022 Jan; 64(1642):12-13. PubMed ID: 35134043
    [No Abstract]   [Full Text] [Related]  

  • 17. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
    Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
    Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. If roflumilast inhibits the innate immunity in the stable patient, what about infection?
    Blasco LM
    Clin Respir J; 2013 Jan; 7(1):e11-2. PubMed ID: 22364166
    [No Abstract]   [Full Text] [Related]  

  • 19. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
    Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
    Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
    Rogliani P; Calzetta L; Cazzola M; Matera MG
    Expert Opin Drug Saf; 2016 Aug; 15(8):1133-46. PubMed ID: 27279341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.